Agilent Acquires Genohm to Improve Lab Informatics

News
Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-06-07-2018
Volume 13
Issue 6

Agilent Technologies expects the acquisition to improve its current software portfolio.

Agilent Technologies announced in a May 2, 2018 press release that it has entered into a definitive agreement to acquire Genohm, a Lausanne, Switzerland-based developer of highly differentiated, on-premise, and cloud-based software solutions for laboratory management.

The transaction is subject to closing conditions. Financial terms of the deal were not disclosed.

Genohm's main laboratory software automation suite, SLIMS, is a digital platform that provides laboratories with a rapidly deployable and seamless laboratory information management system (LIMS) and electronic lab notebook (ELN) environment that is used in biobanks, research labs, and next-generation sequencing facilities. The platform tracks data and samples, tests and users, and results and workflows from the original material shipment to the result from lab instruments and in-silico analysis pipelines. Genohm also has an application marketplace with preconfigured workflows to enable rapid system implementation across a broad range of industries and scientific workflows.

According to Agilent, this acquisition enhances Agilent's current software portfolio, adding LIMS and workflow management while expanding ELN capability.  This combination will allow Agilent to bring greater context to analytical data, enabling scientists to generate results more efficiently.

"Genohm has an excellent footprint in the genomics space," said Kamni Vijay, PhD, vice president and general manager of Agilent's Genomics Division, in the press release. "This acquisition supports our strategy to offer complete next-generation sequencing workflows and improve the laboratory management of our genomic customers."

Source: Agilent

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content